On behalf of the American Heart Association and the American Stroke Association, we are forwarding information about its ARIA Summit: Cardiovascular and Stroke Considerations for β-Amyloid Immunotherapy in Alzheimer’s Disease on May 11 and 12 near Maastricht, The Netherlands. The Summit is being held following the European Stroke Organisation Conference. There are a limited number of spaces still available for this Summit, so if you are interested, please respond as soon as possible, as indicated below.
This day-long, in-person summit will include approximately 75 thought leaders across multi-disciplinary fields, including neurology, neurocritical care, emergency medicine, neuroscience nursing, risk communications, ethics, etc. Insights from the Summit will inform development of a Special Report.
This Summit is a follow-up to a similar ARIA Summit that the Association held in the United States in July 2025, which resulted in the development of key considerations for caring for patients with Alzheimer’s Disease who are at risk for cerebrovascular disease and ARIA (manuscript is pending publication). The objective of the European Summit is to address clinical issues posed by the new anti-amyloid therapies and consider
directions for the future with tailored guidance for Europe.
The American Heart Association ARIA Summit is supported by Eli Lilly and Company. Your participation in the summit will not result in any accrual of relationship with industry.
Event Details:
Location: Château St. Gerlach, Valkenburg, The Netherlands (about 10 minutes from Maastricht)
Date: 13:00 Monday, May 11, 2026 – 13:00 Tuesday, May 12, 2026
To express your interest in attending the Summit, please contact Stephanie Mohl at Stephanie.Mohl@heart.org. The American Heart Association will then follow up with additional information.